OLVG

Running trials

• Not yet recruiting

  Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fraction With Limited Kidney Function Assessments

  NCT07275437· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· PHASE3· Source

• Active, not recruiting

  Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

  NCT05817942· Source

• Active, not recruiting

  A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

  NCT05197049· PHASE3· Source

• Active, not recruiting

  Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

  NCT04608318· PHASE3· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT04033445· PHASE2 PHASE3· Source

• Active, not recruiting

  Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial

  NCT01558921· PHASE3· Source

• Active, not recruiting

  Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

  NCT00005584· PHASE3· Source

• Active, not recruiting

  RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease

  NCT00002462· PHASE3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

  NCT05142722· PHASE3· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· PHASE3· Source

• Completed

  Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold

  NCT02539966· Source

Trial sites

• Onze Lieve Vrouwe Gasthuis12 trials

Conditions

Diseases this institution publishes on or runs trials for.

• CIDP (chronic inflammatory demyelinating polyneuropathy)3 works · 0 trials